A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
A phase 1/2 trial of ABSK141-400mg in advanced solid tumours, run by Abbisko Therapeutics Co, Ltd, now recruiting.
Overview
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) is a phase 1/2 interventional study registered as NCT07417189 by Abbisko Therapeutics Co, Ltd, with 401 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-12-30. Interventions recorded: ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg, ABSK141-1200mg and ABSK141-Recommended Phase 2 dose (RP2D).
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Shares Abbisko Therapeutics and the tag pipeline.
- TrialABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Shares Abbisko Therapeutics and the tag pipeline.
- TrialStudy of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Shares Abbisko Therapeutics and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.